Dr. Sheilds highlighted advances in SCLC care, including chemo-immunotherapy, emerging survival gains from key trials, evolving tumor origins, and the growing role of biomarkers for personalized treatment. Dr. Bunn examined adenocarcinoma to SCLC transformation, often in EGFR-mutant tumors with p53/RB loss. Biopsies are key for diagnosis; outcomes are poor, highlighting need for new trials. Dr. Iyenger reviewed advances in SCLC radiotherapy, stressing optimized thoracic dosing, limited role of consolidation, ongoing PCI debate, and trials combining radiation with immunotherapy. Christine Hahn reviewed emerging SCLC therapies, highlighting durvalumab consolidation benefits, strong results with tarlatamab, promising ADCs, and novel targeted and bispecific agents.